Hepatocellular carcinoma (HCC) is the most common primary malignancy of the liver. It constitutes approximately 5% of all cancers partly due to the high endemic rates of hepatitis B infection 1.
HCC is the fifth most common cancer in the world and is the third most common cause of cancer-related death (after lung and stomach cancer). The incidence of HCC is rising, largely attributed to a rise in hepatitis C infection11.
The demographics are strongly influenced by the regions in which hepatitis B chronic infection is common, which account for over 80% of cases worldwide. The highest prevalence is in Asia.
In western countries the rate is lower and alcohol accounts for a greater proportion of cases.
Risk factors include 1:
- hepatitis B (HBV) infection - 10 % 5 year cumulative risk 5
- hepatitis C (HCV) infection - 30 % 5 year cumulative risk
- alcoholism - 8 % 5 year cumulative risk
- biliary cirrhosis - 5 % 5 year cumulative risk
- food toxins e.g. aflatoxins
- congenital biliary atresia
- inborn errors of metabolism
HCC are typically diagnosed in adults in late middle age or elderly. The tumour is however also identified in the paediatric population where it is the second most common primary liver tumour after hepatoblastoma.
Presentation is variable, and in affluent nations is often found in the setting of screening programs for patients with known risk factors. Otherwise presentation may include:
- constitutional symptoms
- portal hypertension from invasion of the portal vein
- hepatomegally / mass
The origin of HCCs is believed to relate to repeated cycles of necrosis and regeneration, irrespective of cause. In addition the HBV and HCV genome contains genetic material that may predispose cells to accumulate mutations, or disrupts growth control, thus allowing for a second mechanism by which infection with these agents predisposes to HCC 1
Typically HCCs appear pale masses within the liver, and may be unifocal, multifocal or diffusely infiltrative at the time of presentation. Microscopically they range from well differentiated to undifferentiated .
Metastasis occurs in the final stages of disease(IVA) and carry a poor prognosis13-14.The most frequently involved sites are the lung, adrenal glands, lymph nodes, and bone.
Fibrolamellar hepatocellular carcinoma is distinct variant with different demographics and risk factors.
- alpha-fetoprotein (AFP) levels are elevated in 50-75 % of cases.
Hepatocellular carcinomas can have a variety of appearances:
- focal (massive)
- multifocal (nodular)
They receive most of their blood supply from the hepatic artery accounting for its characteristic enhancement pattern : early arterial enhancement with early washout. Hence, a small foci of HCC may be seen within a regenerative liver nodule, as a foci of arterial enhancement (nodule-in-nodule appearance) 15.
Additionally these tumours have a propensity to invade vascular structures, most commonly the portal vein, but also the hepatic veins, IVC and right atrium. One should remember that a large number of patients will have concomitant cirrhosis, and thus be at risk for bland portal vein thrombosis also.
Several pattern may be seen
- focal HCC
- large usually hypodense mass
- may have necrosis / fat / calcification
- multifocal HCC
- multiple masses of variable attenuation lesions
- may also have central hypodense necrotic portions
- diffuse HCC
- may be difficult to distinguish from associated cirrhosis
Enhancement pattern is the key to correct assessment of HCCs. Usually the mass enhances vividly during early arterial (~25 seconds) and then washes out, becoming indistinct or hypodense compared to the rest of the liver at the portal phase.
Additionally they may be associated with a wedge shaped perfusion abnormality due to arterioportal shunts (APS), and this in turn can result in focal fatty change in the normal liver or focal fatty sparing in the diffusely fatty liver 7. A halo of focal fatty sparing may also be seen around an HCC in an otherwise fatty liver 6.
Portal vein tumour thrombus can be distinguished from bland thrombus by demonstrating enhancement.
Variable appearance depending on individual lesion, size, and background liver.
Typically a small focal HCC appears hypo echoic compared to normal liver. Larger lesions are heterogeneous due to fibrosis, fatty change, necrosis and calcification 8. Again a peripheral halo of hypoechogenicity may be seen with focal fatty sparing.
If diffuse it may be difficult to identify or distinguish from cirrhosis.
- iso or hyperintense c.f. surrounding liver
- hyperintensity may be due to
- intratumoural fat 5
- decreased intensity in surrounding liver
T1 C+ (Gd)
- enhancement is usually arterial and may be brief
- rapid wash out becoming hypointense c.f. remainder of the liver (96% specific) 5. This is on account of the supply to HCCs being from the hepatic artery rather than portal vein
- rim enhancement may persist (referred to as a capsule)
- the larger the lesion the more heterogeneous the enhancement
- T2 - variable, typically hyperintense
- post SPIO (Iron oxide) - increases sensitivity in diagnosing small HCC’s
DSA - angiography
- threads and streaks’ pattern - sign of tumour thrombus in portal vein
- hypervascular tumour
There are several staging systems used in hepatocellular carcinoma 16
- Barcelona-Clínic Liver Cancer (BCLC) staging system
- CLIP score
- Okuda staging system
- CUPI (Chinese University Prognostic Index)
- TNM staging
- Japan Integrated Staging (JIS)
- French classification system
Treatment and prognosis
If the lesion is small then resection is possible (partial hepatectomy) and may result in cure, as may liver transplantation with total hepatectomy. The remarkable ability of the liver to regenerate means that up to 2/3rds of the liver can be resected 10. To be suitable for a liver transplantation it is generally agreed that certain criteria should be met (see Milan criteria).
If this is not possible then a variety of options exist including chemotherapy, chemoembolisation, radiofrequency ablation (RFA) and selective internal radiation therapy (SIRT) 12.
If a tumour is resectable, then 5 year survival is at ~ 37-56% 3.
General imaging differential considerations include
- 1. Kumar V, Abbas AK, Fausto N et-al. Robbins and Cotran pathologic basis of disease. W B Saunders Co. (2005) ISBN:0721601871. Read it at Google Books - Find it at Amazon
- 2. Dähnert W. Radiology review manual. Lippincott Williams & Wilkins. (2003) ISBN:0781738954. Read it at Google Books - Find it at Amazon
- 3. Smith MT, Blatt ER, Jedlicka P et-al. Best cases from the AFIP: fibrolamellar hepatocellular carcinoma. Radiographics. 28 (2): 609-13. doi:10.1148/rg.282075153 - Pubmed citation
- 4. Antila KM, Mäkisalo H, Arola J et-al. Best cases from the AFIP: biliary papillomatosis. Radiographics. 28 (7): 2059-63. doi:10.1148/rg.287085010 - Pubmed citation
- 5. Willatt JM, Hussain HK, Adusumilli S et-al. MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology. 2008;247 (2): 311-30. doi:10.1148/radiol.2472061331 - Pubmed citation
- 6. Kim KW, Kim MJ, Lee SS et-al. Sparing of fatty infiltration around focal hepatic lesions in patients with hepatic steatosis: sonographic appearance with CT and MRI correlation. AJR Am J Roentgenol. 2008;190 (4): 1018-27. doi:10.2214/AJR.07.2863 - Pubmed citation
- 7. Choi BI, Lee KH, Han JK et-al. Hepatic arterioportal shunts: dynamic CT and MR features. Korean J Radiol. 3 (1): 1-15. Korean J Radiol (link) - Free text at pubmed - Pubmed citation
- 8. Lau WY. Hepatocellular Carcinoma. World Scientific Pub Co Inc. (2008) ISBN:9812707999. Read it at Google Books - Find it at Amazon
- 9. Grendell JH, Friedman SL, McQuaid KR. Current diagnosis & treatment in gastroenterology. McGraw-Hill Medical. (2003) ISBN:0838515517. Read it at Google Books - Find it at Amazon
- 10. Kelsen D, Daly JM, Kern SE et-al. Principles and practice of gastrointestinal oncology. Lippincott Williams & Wilkins. (2008) ISBN:0781776171. Read it at Google Books - Find it at Amazon
- 11. Parkin DM, Bray F, Ferlay J et-al. Estimating the world cancer burden: Globocan 2000. Int. J. Cancer. 2001;94 (2): 153-6. Int. J. Cancer (link) - Pubmed citation
- 12. Stubbs RS, Wickremesekera SK. Selective internal radiation therapy (SIRT): a new modality for treating patients with colorectal liver metastases. HPB (Oxford). 2004;6 (3): 133-9. doi:10.1080/13651820410025084 - Free text at pubmed - Pubmed citation
- 13. Kummar S, Shafi NQ. Metastatic hepatocellular carcinoma. Clin Oncol (R Coll Radiol). 2003;15 (5): 288-94. Pubmed citation
- 14. Katyal S, Oliver JH, Peterson MS et-al. Extrahepatic metastases of hepatocellular carcinoma. Radiology. 2000;216 (3): 698-703. Radiology (full text) - Pubmed citation
- 15. Parente DB, Perez RM, Eiras-Araujo A et-al. MR imaging of hypervascular lesions in the cirrhotic liver: a diagnostic dilemma. Radiographics. 2012;32 (3): 767-87. doi:10.1148/rg.323115131 - Pubmed citation
- 16. Pons F, Varela M, Llovet JM. Staging systems in hepatocellular carcinoma. HPB (Oxford). 2005;7 (1): 35-41. doi:10.1080/13651820410024058 - Free text at pubmed - Pubmed citation
Synonyms & Alternative Spellings
|Synonyms or Alternative Spelling||Include in Listings?|
|Hepatocellular carcinoma (HCC)||✗|